Products from biotech major Gilead Sciences appear twice on a US Food and Drug Administration (FDA) list of six cell therapies that are to carry black box warni 25 January 2024
The Cell and Gene Therapy Catapult (CGT Catapult), a government-funded body encouraging the development of the advanced therapy sector, has published a report i 18 January 2024
Two new initial public offerings (IPO) are set to go ahead in the USA, raising hopes of a thaw in what has been a long winter for biotech companies going public 17 January 2024
Belgian biotech BioSenic has reached agreement on a binding term sheet with privately-held Australian firm Phebra on the development of the first oral formulati 15 January 2024
Massachusetts, USA-based Dyne Therapeutics has raised $345 million, shortly after announcing encouraging biomarker data for its Duchenne muscular dystrophy (DMD 15 January 2024
The International Society for Cell and Gene Therapy (ISCT) has announced the publication in Nature Medicine of a commentary addressing a statement from the US F 12 January 2024
New York-based TG Therapeutics has entered into an agreement with Precision BioSciences (Nasdaq: DTIL) related to an allogeneic CD19 CAR T cell therapy. 10 January 2024
A commercial stage biopharmaceutical R&D company, focused on the development of products that address the medical challenges in the therapeutic area of anti-infectives.